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Introduction {#sec007}
============

Monoclonal gammopathy (MG) is a prevalent condition \[[@pmed.1003050.ref001]\] that can indicate a malignant B cell disorder such as multiple myeloma, but more often results from a pre-malignant B cell clone with no demonstrable organ damage (MG of undetermined significance, MGUS) \[[@pmed.1003050.ref002],[@pmed.1003050.ref003]\]. MGUS is common, affecting around 3% of those aged over 50 years \[[@pmed.1003050.ref001]\], and requires monitoring but not targeted therapy. However, a non-malignant MG can, rarely, be causally associated with kidney damage (MG of renal significance \[MGRS\]), where specific targeted therapy is indicated to preserve organ function \[[@pmed.1003050.ref004]\].

Several studies in general populations have shown that the presence of MGUS is associated with shorter survival \[[@pmed.1003050.ref005],[@pmed.1003050.ref006]\], and the prevalence of MGUS in patients with chronic kidney disease (CKD) has been reported to be higher than in the general population \[[@pmed.1003050.ref007],[@pmed.1003050.ref008]\]. However, to the best of our knowledge, there has been only 1 small study examining the prognostic significance of MGUS in patients with CKD \[[@pmed.1003050.ref007]\]. The study found that those with MGUS were not at a significantly higher risk of kidney failure or, unlike in the general population, death \[[@pmed.1003050.ref007]\].

This study was performed to determine the prevalence of non-malignant MG in a CKD population and to evaluate whether the presence of a non-malignant MG adds to the risk of adverse outcomes in CKD. We tested the pre-specified hypotheses that the presence of a non-malignant MG is independently associated with a higher risk of kidney failure and shorter survival in patients with CKD.

Methods {#sec008}
=======

A prospective analysis plan was written ([S1 Protocol](#pmed.1003050.s002){ref-type="supplementary-material"}). This study is reported as per the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guideline ([S1 STROBE Checklist](#pmed.1003050.s001){ref-type="supplementary-material"}).

Patients {#sec009}
--------

Patients from 3 prospective UK cohorts of individuals with CKD who had not received kidney replacement therapy (KRT, i.e., dialysis or kidney transplant) were included: Renal Impairment in Secondary Care (RIISC; ClinicalTrials.gov: NCT01722383), the Salford Kidney Study (SKS, previously termed the Chronic Renal Insufficiency Standards Implementation Study \[CRISIS\]), and Renal Risk in Derby (RRID; National Institute for Health Research study ID: 6632).

Each study had research ethics committee (REC) approval (RIISC: West Midlands South Birmingham REC, ref 10/H1207/6; SKS: North West Greater Manchester South REC; ref 15/NW/0818; RRID: East Midlands Nottingham 1 REC). All participants in all 3 studies provided written informed consent, and all studies were conducted in accordance with the Declaration of Helsinki.

Complete details of these cohorts have been reported elsewhere \[[@pmed.1003050.ref009]--[@pmed.1003050.ref011]\], and the inclusion and exclusion criteria are summarised in [Table 1](#pmed.1003050.t001){ref-type="table"}. For this analysis, participants were excluded at an individual level if they had a malignant MG (multiple myeloma or another malignant B cell lymphoproliferative disorder).

10.1371/journal.pmed.1003050.t001

###### Number of participants included and characteristics of each cohort study.

**ACR in mg/mmol; eGFR in ml/min/1.73 m**^**2**^.

![](pmed.1003050.t001){#pmed.1003050.t001g}

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study   Number included   Setting          Inclusion criteria                                                                                                      Exclusion criteria                                         Years of recruitment   End of follow-up   Median (IQR) follow-up (months)
  ------- ----------------- ---------------- ----------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------- ---------------------- ------------------ ---------------------------------
  RIISC   878               Secondary care   \(1\) eGFR \< 30 or (2) eGFR 30--59 with (a) eGFR decline[\*](#t001fn002){ref-type="table-fn"} or (b) urine ACR \> 70   \(1\) Previous dialysis or kidney transplant\              2010 to 2015           End of 2018        74 (64 to 83)
                                                                                                                                                                     (2) Immunosuppression for immune-mediated kidney disease                                             

  SKS     861               Secondary care   eGFR \>10 to \<60                                                                                                       Previous dialysis or kidney transplant                     2002 to 2010           End of 2017        139 (110 to 161)

  RRID    1,739             Primary care     eGFR 30--59                                                                                                             \(1\) Expected survival \<1 year\                          2008 to 2010           End of 2015        61 (60 to 63)
                                                                                                                                                                     (2) Previous solid organ transplant                                                                  
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

eGFR units are ml/min/1.73 m^2^; ACR units are mg/mmol.

\*eGFR decline defined as ≥ 5 ml/min/1.73 m^2^ per year, or ≥ 10 ml/min/1.73 m^2^ over 5 years.

ACR, albumin-to-creatinine ratio; eGFR, estimated glomerular filtration rate; IQR, interquartile range; RIISC, Renal Impairment in Secondary Care; RRID, Renal Risk in Derby; SKS, Salford Kidney Study.

Definition of MG {#sec010}
----------------

Although the majority of included participants with MG will have had MGUS, we have used the more general term non-malignant MG to reflect the fact that only a minority of participants had kidney biopsies to exclude MGRS definitively. Two forms of non-malignant MG were assessed: (1) any non-malignant MG (assessed in the RIISC cohort only), defined as (a) a monoclonal protein on serum protein electrophoresis (SPEP) confirmed by serum immunofixation or (b) a serum κ/λ free light chain (FLC) ratio \< 0.37 or \>3.10 with an increased level of the involved light chain, or (2) light chain MG (LC-MG) (assessed in all 3 cohorts), defined as a serum κ/λ FLC ratio \< 0.37 or \>3.10 with an increased level of the involved light chain.

The Freelite assay (Binding Site, Birmingham, UK) was used to measure κ and λ FLC concentration in all 3 cohorts. The serum κ/λ FLC ratio reference range of 0.37 to 3.10 has been recommended in patients with kidney impairment to account for the associated change in FLC clearance \[[@pmed.1003050.ref012],[@pmed.1003050.ref013]\]. For the RIISC cohort, SPEP and immunofixation were also performed on baseline serum using standard laboratory procedures.

Study design {#sec011}
------------

Patients were recruited prospectively in all 3 cohorts, and data and biological samples collected at baseline visits were used for this analysis. Years of recruitment, end of follow-up, and median follow-up time for each study are given in [Table 1](#pmed.1003050.t001){ref-type="table"}. Time-to-event data were collected for 2 clinical endpoints: (1) kidney failure (defined as the initiation of KRT) and (2) death.

The following variables were available for analysis: age, sex, ethnicity (white, black, South Asian, or other), smoking status (current smoker, previous smoker, never smoked), co-morbidities (diabetes mellitus \[DM\], ischaemic heart disease \[IHD\], cerebrovascular disease, peripheral artery disease \[PAD\], chronic obstructive pulmonary disease \[COPD\], and malignancy), cause of CKD (vascular, diabetes, glomerular, tubulointerstitial, cystic or congenital, or other or unknown), mean arterial pressure (MAP), estimated glomerular filtration rate (eGFR, calculated using the 4-variable Modification of Diet in Renal Disease formula), and urine albumin-to-creatinine ratio (ACR).

No formal sample size calculations were carried out for these analyses, which were performed using the available specimen collections and datasets.

Statistical analysis {#sec012}
--------------------

Missing data were assumed to be missing at random, and multiple imputation using chained equations was performed. Results of complete case analyses were similar and are provided in [S1](#pmed.1003050.s003){ref-type="supplementary-material"} and [S2](#pmed.1003050.s004){ref-type="supplementary-material"} Tables.

Continuous variables all had skewed distributions as assessed by histograms. The relationships of MG or LC-MG status with other categorical baseline variables were assessed using Fisher's exact test, and relationships with continuous variables were assessed using the Wilcoxon rank-sum test.

The prognostic significance of an MG or LC-MG for risk of kidney failure was estimated by competing-risks regression (the Fine and Gray method \[[@pmed.1003050.ref014]\]) to account for the competing risk of death, and expressed as a subhazard ratio (SHR) with 95% confidence interval (CI). The associations with risk of death were estimated using Cox proportional hazards models and expressed as hazard ratios (HRs) with 95% CI. Log--log plots were assessed for each variable to ensure that the proportional hazards assumption was not violated. Following an initial statistical review of our study, robust estimates of variance were used in all regression models, which are less sensitive to the presence of outliers. In analyses that included amalgamated data from all 3 cohorts, clustering was accounted for by the use of stratified models, in which the baseline hazard is allowed to vary by cohort. However, the estimated coefficient for a particular predictor variable is equal across cohorts.

All variables included in multivariable models were pre-specified, based on established prognostic factors for kidney failure and death in patients with CKD. Dummy variables were created for categorical variables with more than 2 categories, and fractional polynomials were used to explore the presence of non-linear relationships between continuous predictors and each outcome. Where fractional polynomials provided a better model fit, plots of risk against the variable on its original scale are presented to aid appreciation of the non-linear relationship.

Results {#sec013}
=======

Any non-malignant MG {#sec014}
--------------------

In total, 878 participants from the RIISC cohort were included, and 102 (11.6%) of these had an MG. Types of MG were as follows: 63 (61.8%) were IgG, 8 (7.8%) were IgM, 5 (4.9%) were IgA, 1 (1.0%) was biclonal (IgG and IgM), and 25 (24.5%) were LC-MG. Study population characteristics and the relationship between MG status and other baseline variables are shown in [Table 2](#pmed.1003050.t002){ref-type="table"}. Compared to those without an MG, those with an MG were on average older (*P* \< 0.001), and a higher proportion had a history of malignancy (*P* = 0.037). For all other baseline variables, there were no statistically significant differences between those with and those without an MG.

10.1371/journal.pmed.1003050.t002

###### Baseline characteristics of 878 participants of the RIISC study with CKD by MG status.

![](pmed.1003050.t002){#pmed.1003050.t002g}

  Variable                              All                   With MG               Without MG            Completeness of data (%)
  ------------------------------------- --------------------- --------------------- --------------------- --------------------------
  ***N* (%)**                           878                   102 (11.6)            776 (88.4)            100
  **Age (years)**                       64.6 (51.7 to 76.0)   73.8 (59.8 to 81.4)   63.7 (50.2 to 75.5)   100
  **Sex male**                          542 (61.7)            66 (64.7)             476 (61.3)            100
  **Ethnicity**                                                                                           100
  White                                 598 (68.1)            68 (66.7)             530 (68.3)            
  South Asian                           188 (21.4)            24 (23.5)             164 (21.1)            
  Black                                 84 (9.6)              9 (8.9)               75 (9.7)              
  Other                                 8 (0.9)               1 (1.0)               7 (0.9)               
  **Co-morbidities**                                                                                      100
  DM                                    341 (38.8)            48 (47.1)             293 (37.8)            
  IHD                                   208 (23.7)            30 (29.4)             178 (22.9)            
  Cerebrovascular disease               102 (11.6)            15 (14.7)             87 (11.2)             
  PAD                                   93 (10.6)             14 (13.7)             79 (10.2)             
  COPD                                  89 (10.1)             8 (7.8)               81 (10.4)             
  Malignancy                            128 (14.6)            22 (21.6)             106 (13.7)            
  **Smoking status**                                                                                      98.2
  Never                                 416 (48.3)            47 (47.0)             369 (48.4)            
  Previous                              333 (38.6)            40 (40.0)             293 (38.5)            
  Current                               113 (13.1)            13 (13.0)             100 (13.1)            
  **Cause of CKD**                                                                                        91.2
  Vascular                              230 (28.7)            34 (36.2)             196 (27.7)            
  Diabetes                              125 (15.6)            20 (21.3)             105 (14.9)            
  Glomerular                            109 (13.6)            7 (7.4)               102 (14.4)            
  Tubulointerstitial                    89 (11.1)             6 (6.4)               83 (11.7)             
  Cystic or congenital                  66 (8.2)              4 (4.3)               62 (8.8)              
  Other or unknown                      182 (22.7)            23 (24.5)             159 (22.5)            
  **MAP (mm Hg)**                       93 (85 to 102)        92 (83 to 103)        93 (86 to 102)        97.6
  **eGFR (ml/min/1.73 m**^**2**^**)**   31 (23 to 42)         28 (22 to 42)         31 (23 to 42)         96.8
  **Urine ACR (mg/mmol)**               33.4 (6.3 to 130.0)   32.7 (5.6 to 161.2)   33.4 (6.5 to 122.7)   94.0

Categorical variables are shown as frequency (percentage), and continuous variables as median (interquartile range).

ACR, albumin-to-creatinine ratio; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; DM, diabetes mellitus; eGFR, estimated glomerular filtration rate; IHD, ischaemic heart disease; MAP, mean arterial pressure; MG, monoclonal gammopathy; PAD, peripheral artery disease; RIISC, Renal Impairment in Secondary Care.

Kidney failure {#sec015}
--------------

In total, 327 (37.2%) participants progressed to kidney failure, with rates per 100 person-years of 10.5 and 9.3 for those with and without MG, respectively. The univariable associations between baseline variables and the risk of kidney failure are shown in [Table 2](#pmed.1003050.t003){ref-type="table"}. Age, eGFR, and urine ACR had non-linear relationships with the risk of kidney failure ([Fig 1](#pmed.1003050.g001){ref-type="fig"}). The presence of an MG did not have a significant association with the risk of kidney failure (SHR 0.97 \[95% CI 0.68 to 1.38\], *P* = 0.85; [Fig 2](#pmed.1003050.g002){ref-type="fig"}).

![Non-linear univariable associations with risk of kidney failure in 878 participants of the Renal Impairment in Secondary Care study with chronic kidney disease for age (relative to 60 years), estimated glomerular filtration rate (eGFR, relative to 30 ml/min/1.73 m^2^), and urine albumin-to-creatinine ratio (ACR, relative to 30 mg/mmol).](pmed.1003050.g001){#pmed.1003050.g001}

![Cumulative incidence function for kidney failure in 878 participants of the Renal Impairment in Secondary Care study with chronic kidney disease, by presence or absence of monoclonal gammopathy (MG).\
MG present (black line); MG absent (grey line). Dashed lines represent 95% CIs.](pmed.1003050.g002){#pmed.1003050.g002}

10.1371/journal.pmed.1003050.t003

###### Association between baseline variables and risk of kidney failure (competing-risks regression, expressed as SHR with 95% CI) and death (Cox proportional hazards regression, expressed as HR with 95% CI) in 878 participants from the RIISC study with CKD.

![](pmed.1003050.t003){#pmed.1003050.t003g}

  Variable                  Kidney failure   Death                                                                                                                
  ------------------------- ---------------- -------------- --------- --------- -------------- --------- --------- -------------- --------- ------ -------------- ---------
  **With MG**               0.97             0.68 to 1.38   0.85      1.16      0.80 to 1.69   0.43      2.13      1.49 to 3.02   \<0.001   1.37   0.93 to 2.00   0.11
  **Age**                   1.00^a^          1.00 to 1.00   \<0.001   1.00^a^   0.99 to 1.00   \<0.001   3.36      2.73 to 4.12   \<0.001   2.83   2.21 to 3.64   \<0.001
  **Male sex**              0.99             0.79 to 1.23   0.92      0.55      0.44 to 0.69   \<0.001   1.27      0.95 to 1.69   0.11      0.88   0.62 to 1.24   0.46
  **Ethnicity**                                                                                                                                                   
  White                     Ref                                       Ref                                Ref                                Ref                   
  South Asian               2.02             1.58 to 2.57   \<0.001   1.29      0.98 to 1.69   0.07      0.51      0.33 to 0.78   0.002     0.91   0.58 to 1.42   0.67
  Black                     1.98             1.42 to 2.76   \<0.001   1.77      1.32 to 2.38   \<0.001   0.80      0.48 to 1.33   0.39      1.13   0.67 to 1.90   0.65
  Other                     2.64             1.07 to 6.55   0.036     1.82      0.91 to 3.62   0.09      0.56      0.08 to 3.86   0.56      0.66   0.16 to 2.72   0.57
  **Co-morbidities**                                                                                                                                              
  DM                        0.92             0.73 to 1.15   0.46                                         1.64      1.25 to 2.16   \<0.001   1.27   0.94 to 1.72   0.12
  IHD                       0.85             0.65 to 1.11   0.22                                         2.44      1.83 to 3.24   \<0.001   1.44   1.05 to 1.96   0.022
  Cerebrovascular disease   0.77             0.53 to 1.13   0.18                                         1.97      1.38 to 2.81   \<0.001   1.27   0.87 to 1.85   0.21
  PAD                       0.86             0.59 to 1.27   0.45                                         2.21      1.57 to 3.11   \<0.001   1.27   0.85 to 1.91   0.24
  COPD                      0.45             0.28 to 0.72   0.001                                        1.46      0.99 to 2.16   0.06      1.14   0.74 to 1.77   0.55
  Malignancy                0.51             0.35 to 0.76   0.001                                        2.16      1.56 to 2.99   \<0.001   1.56   1.10 to 2.22   0.013
  **Smoking status**                                                                                                                                              
  Never                     Ref                                                                          Ref                                Ref                   
  Previous                  0.69             0.54 to 0.88   0.003                                        1.73      1.28 to 2.34   \<0.001   1.06   0.76 to 1.49   0.74
  Current                   1.07             0.78 to 1.47   0.71                                         1.14      0.71 to 1.84   0.58      1.25   0.70 to 2.24   0.45
  **Cause of CKD**                                                                                                                                                
  Vascular                  Ref                                       Ref                                Ref                                                      
  Diabetes                  1.92             1.33 to 2.78   0.001     1.05      0.69 to 1.60   0.81      0.81      0.52 to 1.26   0.35                            
  Glomerular                1.19             0.81 to 1.76   0.38      1.00      0.66 to 1.51   1.00      0.22      0.11 to 0.41   \<0.001                         
  Tubulointerstitial        0.89             0.57 to 1.38   0.59      0.63      0.37 to 1.06   0.08      0.31      0.16 to 0.59   \<0.001                         
  Cystic or congenital      2.85             2.01 to 4.04   \<0.001   3.99      2.74 to 5.83   \<0.001   0.26      0.10 to 0.63   0.003                           
  Other or unknown          1.24             0.89 to 1.73   0.21      1.21      0.85 to 1.73   0.28      0.82      0.57 to 1.17   0.27                            
  **MAP**                   1.39             1.25 to 1.54   \<0.001   0.93      0.83 to 1.06   0.28      0.79      0.68 to 0.93   0.005                           
  **eGFR**                                                                                                                                                        
                            1.18^b^          1.14 to 1.22   \<0.001   0.94^b^   0.93 to 0.96   \<0.001   0.45      0.36 to 0.56   \<0.001   0.67   0.53 to 0.86   0.002
                            1.06^c^          1.05 to 1.07   \<0.001   3.26^d^   2.73 to 3.91   \<0.001                                                            
  **Urine ACR**                                                                                                                                                   
                            1.48^e^          1.37 to 1.59   \<0.001   3.30^f^   2.61 to 4.17   \<0.001   0.78^g^   0.63 to 0.96   0.018     1.24   1.07 to 1.45   0.005
                                                                      1.00^a^   1.00 to 1.00   \<0.001   1.01^a^   1.00 to 1.01   \<0.001                         

Continuous variables are linear per 1 standard deviation unless otherwise indicated. Transformed continuous variables are indicated by the following footnotes: (a) *x*^3^; (b) *x*^−2^; (c) *x*^-2^ln(*x*); (d) *x*^−1^; (e) ln(*x*); (f) *x*^0.5^; (g) *x*. Two rows for a continuous variable indicate the SHR or HR for each power of the degree-2 fractional polynomial transformation. Cells for variables not included in a particular multivariable model are shaded grey.

ACR, albumin-to-creatinine ratio; CI, confidence interval; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; DM, diabetes mellitus; eGFR, estimated glomerular filtration rate; HR, hazard ratio; IHD, ischaemic heart disease; MAP, mean arterial pressure; MG, monoclonal gammopathy; PAD, peripheral artery disease; RIISC, Renal Impairment in Secondary Care; SHR, subhazard ratio.

The multivariable model for kidney failure is shown in [Table 2](#pmed.1003050.t003){ref-type="table"}. After adjustment for age, sex, ethnicity, cause of CKD, MAP, eGFR, and urine ACR, the presence of an MG was not significantly associated with risk of kidney failure (SHR 1.16 \[95% CI 0.80 to 1.69\], *P* = 0.43). Younger age, female sex, black ethnicity, a cystic or congenital cause of CKD, a lower eGFR, and a higher urine ACR were all associated with a higher risk of kidney failure. In this multivariable model, age, eGFR, and urine ACR had non-linear associations with risk of kidney failure ([Fig 3](#pmed.1003050.g003){ref-type="fig"}).

![Non-linear associations with risk of kidney failure in 878 participants of the Renal Impairment in Secondary Care study with chronic kidney disease (CKD) in a multivariable model containing monoclonal gammopathy status, age, sex, ethnicity, cause of CKD, mean arterial pressure, estimated glomerular filtration rate (eGFR), and urine albumin-to-creatinine ratio (ACR), for age (relative to 60 years), eGFR (relative to 30 ml/min/1.73 m^2^), and urine ACR (relative to 30 mg/mmol).](pmed.1003050.g003){#pmed.1003050.g003}

Death {#sec016}
-----

In total, 202 (23.0%) participants died. The death rates per 100 person-years were 10.8 and 5.3 for those with and without MG, respectively. The presence of an MG was associated with a higher risk of death in the univariable model (HR 2.13 \[95% CI 1.49 to 3.02\], *P* \< 0.001), as shown in [Table 2](#pmed.1003050.t003){ref-type="table"} and [Fig 4](#pmed.1003050.g004){ref-type="fig"}. However, in the multivariable model, adjusting for age, sex, ethnicity, co-morbidities, smoking status, eGFR, and urine ACR, the presence of an MG no longer had a statistically significant association with death (HR 1.37 \[95% CI 0.93 to 2.00\], *P* = 0.11; [Table 2](#pmed.1003050.t003){ref-type="table"}). Older age, a history of IHD or malignancy, lower eGFR, and higher urine ACR were associated with a higher risk of death.

![Kaplan--Meier survival curves for 878 participants of the Renal Impairment in Secondary Care study with chronic kidney disease by the presence or absence of monoclonal gammopathy (MG).\
MG present (black line); MG absent (grey line).](pmed.1003050.g004){#pmed.1003050.g004}

Non-malignant LC-MG {#sec017}
-------------------

In total, 3,478 participants from the 3 cohorts were included, and 55 (1.6%) of these had an LC-MG. [Table 3](#pmed.1003050.t004){ref-type="table"} shows the study population characteristics and the relationship between LC-MG status and other baseline variables. Compared to those without an LC-MG, those with an LC-MG were on average older (*P* \< 0.001), a higher proportion were male (*P* = 0.006) and of black ethnicity (*P* = 0.004), and a lower proportion had a history of IHD (*P* = 0.001) or PAD (*P* = 0.004). There were no statistically significant differences between those with and those without LC-MG with respect to all other baseline variables.

10.1371/journal.pmed.1003050.t004

###### Baseline characteristics for 3,478 participants with CKD from 3 cohort studies, by LC-MG status.

![](pmed.1003050.t004){#pmed.1003050.t004g}

  Variable                              All                   With LC-MG            Without LC-MG         Completeness of data (%)
  ------------------------------------- --------------------- --------------------- --------------------- --------------------------
  ***N* (%)**                           3,478                 55 (1.6)              3,423 (98.4)          
  **Age (years)**                       71.0 (61.2 to 78.0)   77.8 (71.0 to 82.0)   71.0 (61.1 to 78.0)   100
  **Sex (male)**                        1,760 (50.6)          38 (69.1)             1,722 (50.3)          100
  **Ethnicity**                                                                                           100
  White                                 3,126 (89.9)          44 (80.0)             3,082 (90.0)          
  South Asian                           237 (6.8)             5 (9.1)               232 (6.8)             
  Black                                 96 (2.8)              6 (10.9)              90 (2.6)              
  Other                                 19 (0.6)              0 (0.0)               19 (0.6)              
  **Co-morbidities**                                                                                      100
  DM                                    914 (26.3)            16 (29.1)             898 (26.2)            
  IHD                                   1,347 (38.7)          10 (18.2)             1,337 (39.1)          
  Cerebrovascular disease               395 (11.4)            3 (5.5)               392 (11.5)            
  PAD                                   879 (25.3)            5 (9.1)               874 (25.5)            
  **Smoking status**                                                                                      99.5
  Never                                 1,486 (43.0)          26 (47.3)             1,460 (42.9)          
  Previous                              1,667 (48.2)          28 (50.9)             1,639 (48.1)          
  Current                               307 (8.9)             1 (1.8)               306 (9.0)             
  **MAP (mm Hg)**                       93 (86 to 102)        92 (85 to 99)         93 (86 to 102)        99.3
  **eGFR (ml/min/1.73 m**^**2**^**)**   42.3 (26.2 to 54.4)   40.4 (24.3 to 54.2)   42.3 (26.3 to 54.4)   99.2
  **Urine ACR (mg/mmol)**               3.4 (0.3 to 27.3)     4.7 (0.4 to 76.6)     3.4 (0.2 to 26.7)     95.5

Categorical variables are shown as frequency (percentage), and continuous variables as median (interquartile range).

ACR, albumin-to-creatinine ratio; CKD, chronic kidney disease; DM, diabetes mellitus; eGFR, estimated glomerular filtration rate; IHD, ischaemic heart disease; LC-MG, light chain monoclonal gammopathy; MAP, mean arterial pressure; PAD, peripheral artery disease.

Kidney failure {#sec018}
--------------

In total, 564 (16.2%) patients progressed to kidney failure, with rates per 100 person-years of 4.9 and 3.2 for those with and without an LC-MG, respectively. The univariable associations between baseline variables and the risk of kidney failure are shown in [Table 5](#pmed.1003050.t005){ref-type="table"}. Age, eGFR, and urine ACR had non-linear associations with risk of kidney failure in the univariable analyses ([Fig 5](#pmed.1003050.g005){ref-type="fig"}). The presence of an LC-MG did not have a significant association with the risk of kidney failure (SHR 1.07 \[95% CI 0.58 to 1.96\], *P* = 0.82; [Fig 6](#pmed.1003050.g006){ref-type="fig"}).

![Non-linear univariable associations with risk of kidney failure in 3,478 participants with chronic kidney disease from 3 cohort studies for age (relative to 70 years), estimated glomerular filtration rate (eGFR, relative to 40 ml/min/1.73 m^2^), and urine albumin-to-creatinine ratio (ACR, relative to 3 mg/mmol).](pmed.1003050.g005){#pmed.1003050.g005}

![Cumulative incidence function for kidney failure in 3,478 participants with chronic kidney disease from 3 cohort studies, by the presence or absence of light chain monoclonal gammopathy (LC-MG).\
LC-MG present (black line); LC-MG absent (grey line). Dashed lines represent 95% CIs.](pmed.1003050.g006){#pmed.1003050.g006}

10.1371/journal.pmed.1003050.t005

###### Association between baseline variables and risk of kidney failure (competing-risks regression, expressed as SHR with 95% CI) and death (Cox proportional hazards regression, expressed as HR with 95% CI) in 3,478 participants with CKD from 3 cohort studies.

![](pmed.1003050.t005){#pmed.1003050.t005g}

  Variable                  Kidney failure   Death                                                                                                                       
  ------------------------- ---------------- --------------- --------- --------- -------------- --------- ---------- ---------------- --------- --------- -------------- ---------
  **With LC-MG**            1.07             0.58 to 1.96    0.82      1.42      0.78 to 2.57   0.26      2.51       1.59 to 3.96     \<0.001   1.49      0.93 to 2.39   0.10
  **Age**                                                                                                                                                                
                            1.01^a^          1.00 to 1.02    0.20      1.00^a^   1.00 to 1.00   \<0.001   2.88       2.60 to 3.19     \<0.001   2.76      2.48 to 3.08   \<0.001
                            1.00^b^          0.99 to 1.00    0.050                                                                                                       
  **Male sex**              0.95             0.81 to 1.12    0.53      1.14      0.96 to 1.37   0.13      1.59       1.37 to 1.84     \<0.001   1.27      1.09 to 1.49   0.002
  **Ethnicity**                                                                                                                                                          
  White                     Ref                                        Ref                                Ref                                   Ref                      
  South Asian               1.94             1.56 to 2.41    \<0.001   1.15      0.89 to 1.48   0.30      0.67       0.47 to 0.94     0.022     1.11      0.79 to 1.56   0.56
  Black                     1.84             1.35 to 2.49    \<0.001   1.71      1.29 to 2.27   \<0.001   0.77       0.48 to 1.25     0.30      1.10      0.70 to 1.73   0.69
  Other                     2.80             1.34 to 5.86    0.006     1.42      0.55 to 3.62   0.47      0.48       0.12 to 1.94     0.30      0.79      0.29 to 2.14   0.64
  **Co-morbidities**                                                                                                                                                     
  DM                        0.92             0.77 to 1.09    0.31                                         1.71       1.48 to 1.97     \<0.001   1.42      1.22 to 1.65   \<0.001
  IHD                       1.03             0.85 to 1.24    0.78                                         1.64       1.35 to 1.99     \<0.001   1.31      1.10 to 1.56   0.002
  Cerebrovascular disease   0.84             0.64 to 1.10    0.20                                         1.97       1.65 to 2.36     \<0.001   1.39      1.15 to 1.69   0.001
  PAD                       1.10             0.88 to 1.36    0.41                                         0.93       0.70 to 1.22     0.58      0.93      0.76 to 1.14   0.49
  **Smoking status**                                                                                                                                                     
  Never                     Ref                                                                           Ref                                   Ref                      
  Previous                  0.72             0.60 to 0.86    \<0.001                                      1.71       1.47 to 2.00     \<0.001   1.26      1.07 to 1.48   0.005
  Current                   1.14             0.91 to 1.44    0.26                                         1.34       1.04 to 1.74     0.026     1.56      1.16 to 2.09   0.003
  **MAP**                                                                                                                                                                
                            1.33             1.23 to 1.44    \<0.001   1.07      0.97 to 1.18   0.16      0.00^c^    0.00 to 0.00     \<0.001                            
                                                                                                          71.39^d^   6.10 to 835.26   0.001                              
  **eGFR**                                                                                                                                                               
                            1.17^e^          1.15 to 1.20    \<0.001   0.96^e^   0.95 to 0.97   \<0.001   0.00^f^    0.00 to 0.01     \<0.001   0.65      0.58 to 0.74   \<0.001
                            1.06^g^          1.05 to 1.06    \<0.001   2.4^h^    2.10 to 2.80   \<0.001                                                                  
  **Urine ACR**                                                                                                                                                          
                            10.97^i^         7.20 to 16.70   \<0.001   3.58^i^   2.62 to 4.90   \<0.001   1.68^i^    1.18 to 2.40     0.005     1.15^c^   1.09 to 1.22   \<0.001
                            0.80^f^          0.68 to 0.95    0.008                                        0.40^j^    0.29 to 0.55     \<0.001   1.01^d^   1.00 to 1.01   \<0.001

Continuous variables are linear per 1 standard deviation unless otherwise indicated. Transformed continuous variables are indicated by the following footnotes: (a) *x*^3^; (b) *x*^3^ln(*x*); (c) ln(*x*); (d) \[ln(*x*)\]^2^; (e) *x*^−2^; (f) *x*^2^; (g) *x*^−2^ln(*x*); (h) *x*^−1^; (i) *x*^0.5^; (j) *x*^0.5^ln(*x*). Two rows for a continuous variable indicate the SHR or HR for each power of the degree-2 fractional polynomial transformation. Cells for variables not included in a particular multivariable model are shaded grey.

ACR, albumin-to-creatinine ratio; CI, confidence interval; CKD, chronic kidney disease; DM, diabetes mellitus; eGFR, estimated glomerular filtration rate; HR, hazard ratio; IHD, ischaemic heart disease; LC-MG, light chain monoclonal gammopathy; MAP, mean arterial pressure; PAD, peripheral artery disease; SHR, subhazard ratio.

The multivariable model for kidney failure is shown in [Table 5](#pmed.1003050.t005){ref-type="table"}. After adjusting for age, sex, ethnicity, MAP, eGFR, and urine ACR, the presence of an LC-MG did not have a statistically significant association with risk of kidney failure (SHR 1.42 \[95% CI 0.78 to 2.57\], *P* = 0.26). In this multivariable model, a younger age, black ethnicity, a lower eGFR, and a higher urine ACR were associated with a higher risk of kidney failure, and the non-linear associations with age, eGFR, and urine ACR are shown in [Fig 7](#pmed.1003050.g007){ref-type="fig"}.

![Non-linear associations with risk of kidney failure in 3,478 participants with chronic kidney disease from 3 cohort studies in a multivariable model containing light chain monoclonal gammopathy status, age, sex, ethnicity, mean arterial pressure, estimated glomerular filtration rate (eGFR), and urine albumin-to-creatinine ratio (ACR), for age (relative to 70 years), eGFR (relative to 40 ml/min/1.73 m^2^), and urine ACR (relative to 3 mg/mmol).](pmed.1003050.g007){#pmed.1003050.g007}

Death {#sec019}
-----

In total, 803 (23.1%) participants died. Death rates were 9.3 and 4.5 per 100 person-years for those with and without an LC-MG, respectively. The univariable associations between baseline factors and death are shown in [Table 5](#pmed.1003050.t005){ref-type="table"}. LC-MG was associated with a higher risk of death (HR 2.51 \[95% CI 1.59 to 3.96\], *P* \< 0.001), and [Fig 8](#pmed.1003050.g008){ref-type="fig"} shows Kaplan--Meier survival curves by LC-MG status. The univariable analyses showed that MAP, eGFR, and urine ACR had non-linear associations with risk of death ([Fig 9](#pmed.1003050.g009){ref-type="fig"}). In the multivariable model ([Table 5](#pmed.1003050.t005){ref-type="table"}), after adjustment for age, sex, ethnicity, co-morbidities, smoking status, eGFR, and urine ACR, the presence of an LC-MG did not have a statistically significant association with death (HR 1.49 \[95% CI 0.93 to 2.39\], *P* = 0.10). In this multivariable model, older age; male sex; a history of DM, IHD, or cerebrovascular disease; being a previous or current smoker, a lower eGFR, and a higher urine ACR (non-linear association; [Fig 10](#pmed.1003050.g010){ref-type="fig"}) were associated with a higher risk of death.

![Kaplan--Meier survival curves for 3,478 participants with chronic kidney disease from 3 cohort studies by the presence or absence of light chain monoclonal gammopathy (LC-MG).\
LC-MG present (black line); LC-MG absent (grey line).](pmed.1003050.g008){#pmed.1003050.g008}

![Non-linear univariable associations with risk of death in 3,478 participants with chronic kidney disease from 3 cohort studies for mean arterial pressure (relative to 90 mm Hg), estimated glomerular filtration rate (eGFR, relative to 40 ml/min/1.73 m^2^), and urine albumin-to-creatinine ratio (ACR, relative to 3 mg/mmol).](pmed.1003050.g009){#pmed.1003050.g009}

![Non-linear association of urine albumin-to-creatinine ratio (ACR, relative to 3 mg/mmol) with risk of death in 3,478 participants with chronic kidney disease from 3 cohort studies in a multivariable model containing light chain monoclonal gammopathy status, age, sex, ethnicity, co-morbidities, smoking status, estimated glomerular filtration rate, and urine ACR.](pmed.1003050.g010){#pmed.1003050.g010}

Discussion {#sec020}
==========

We evaluated the prognostic significance of non-malignant MG in patients with CKD. We found the prevalence of non-malignant MG to be higher in our CKD population compared to reported estimates of prevalence for the general population \[[@pmed.1003050.ref001]\]. However, the presence of an MG was not associated with a higher risk of kidney failure or death after accounting for established prognostic factors in CKD.

To the best of our knowledge, only 1 other study, by Haynes et al. \[[@pmed.1003050.ref007]\], has assessed the relationship between MG and clinical outcomes in patients with CKD. Compared to our study, that by Haynes et al. had far fewer participants (382), such that only 35 patients had MGUS. Therefore, there is likely to be less bias in our estimates of the risk of kidney failure or death associated with an MG in CKD.

The results of our study and the study by Haynes et al. suggest that the shorter survival associated with MGUS in the general population is not seen in patients with CKD. It is possible that neither study was large enough to detect a small increase in the risk of death. However, it may be that the already significantly increased rate of death in individuals with CKD compared to individuals without CKD renders any risk associated with an MG, which is primarily due to malignant transformation over time, negligible.

Our finding of a higher prevalence of MG in CKD is also consistent with the study by Haynes et al. and appears attributable to an increased prevalence of both intact immunoglobulin MG and LC-MG. The prevalence of total MGUS in the Olmsted County cohort in individuals aged 70--79 was 5.9%, and the prevalence of light chain MGUS was 1.1% \[[@pmed.1003050.ref015]\]; in our study, the crude prevalence was 11.6% for total MGUS (median age 73.8 years) and 1.6% for light chain MGUS (median age 77.8 years).

A significant strength of this study was the inclusion of participants from multiple cohorts from both primary and secondary care and that it is the largest cohort to date of patients with MGUS and CKD. A significant limitation was the absence of SPEP and immunofixation data from the SKS and RRID cohorts. We could, therefore, detect only LC-MG in these cohorts, and many patients with an intact Ig MG would not have been identified. However, in the RIISC study, where SPEP and immunofixation were performed on serum from all participants, the presence of any non-malignant MG was not associated with a higher risk of kidney failure or death.

Further, we did not assess the association of MGUS in this CKD population with other clinically important outcomes that are associated with MGUS in those without CKD, such as cardiovascular events, infections, or the evolution of an MG to multiple myeloma or other paraprotein-related diseases. We also did not examine CKD progression (via change in eGFR) with time, which would be a more sensitive marker for MG-associated kidney damage than the outcome of kidney failure.

Further research is required concerning the prognostic implications of non-malignant MG in patients with CKD. However, based on the results of our study, these patients and their healthcare providers may be reassured that the presence of an MG does not significantly increase the risk of kidney failure or death that is associated with CKD.

In conclusion, the prevalence of non-malignant MG appears to be higher in patients with CKD than in the general population. However, its presence is not independently associated with a significantly higher risk of kidney failure or death.

Supporting information {#sec021}
======================
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###### Complete case analyses of the association between baseline variables and risk of kidney failure (competing-risks regression, expressed as SHR with 95% CI) and death (Cox proportional hazards regression, expressed as HR with 95% CI) in 878 participants from the RIISC study with CKD.

Continuous variables are linear per 1 standard deviation unless otherwise indicated. Transformed continuous variables are indicated by the following footnotes: (a) *x*^3^; (b) *x*^−2^; (c) *x*^-2^ln(*x*); (d) ln(*x*); (e) *x*^−1^; (f) *x*^0.5^. ACR, albumin-to-creatinine ratio; CI, confidence interval; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; DM, diabetes mellitus; eGFR, estimated glomerular filtration rate; HR, hazard ratio; IHD, ischaemic heart disease; MAP, mean arterial pressure; MG, monoclonal gammopathy; PAD, peripheral artery disease; RIISC, Renal Impairment in Secondary Care; SHR, subhazard ratio.

(DOCX)
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###### Complete case analyses of the association between baseline variables and risk of kidney failure (competing-risks regression, expressed as SHR with 95% CI) and death (Cox proportional hazards regression, expressed as HR with 95% CI) in 3,478 participants with CKD from 3 cohort studies.

Continuous variables are linear per 1 standard deviation unless otherwise indicated. Transformed continuous variables are indicated by the following footnotes: (a) *x*^3^; (b) *x*^-2^; (c) *x*^−2^ln(*x*); (d) *x*^0.5^; (e) *x*^2^; (f) *x*^−1^; (g) ln(*x*); (h) \[ln(*x*)\]^2^; (i) *x*^0.5^ln(*x*). ACR, albumin-to-creatinine ratio; CI, confidence interval; CKD, chronic kidney disease; DM, diabetes mellitus; eGFR, estimated glomerular filtration rate; HR, hazard ratio; IHD, ischaemic heart disease; LC-MG, light chain monoclonal gammopathy; MAP, mean arterial pressure; PAD, peripheral artery disease; SHR, subhazard ratio.
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Click here for additional data file.

ACR

:   albumin-to-creatinine ratio

CKD

:   chronic kidney disease

COPD

:   chronic obstructive pulmonary disease

DM

:   diabetes mellitus

eGFR

:   estimated glomerular filtration rate

FLC

:   free light chain

HR

:   hazard ratio

IHD

:   ischaemic heart disease

KRT

:   kidney replacement therapy

LC-MG

:   light chain monoclonal gammopathy

MAP

:   mean arterial pressure

MG

:   monoclonal gammopathy

MGRS

:   monoclonal gammopathy of renal significance

MGUS

:   monoclonal gammopathy of undetermined significance

PAD

:   peripheral artery disease

RIISC

:   Renal Impairment in Secondary Care

RRID

:   Renal Risk in Derby

SHR

:   subhazard ratio

SKS

:   Salford Kidney Study

SPEP

:   serum protein electrophoresis
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15 Nov 2019

Dear Dr. Fenton,

Thank you very much for submitting your manuscript \"Association between non-malignant monoclonal gammopathy and adverse outcomes in chronic kidney disease\" (PMEDICINE-D-19-03271) for consideration at PLOS Medicine.

Your paper was evaluated by a senior editor and discussed among all the editors here. It was also discussed with an academic editor with relevant expertise, and sent to independent reviewers, including a statistical reviewer. The reviews are appended at the bottom of this email and any accompanying reviewer attachments can be seen via the link below:

\[LINK\]

In light of these reviews, I am afraid that we will not be able to accept the manuscript for publication in the journal in its current form, but we would like to consider a revised version that addresses the reviewers\' and editors\' comments. Obviously we cannot make any decision about publication until we have seen the revised manuscript and your response, and we plan to seek re-review by one or more of the reviewers.

In revising the manuscript for further consideration, your revisions should address the specific points made by each reviewer and the editors. Please also check the guidelines for revised papers at <http://journals.plos.org/plosmedicine/s/revising-your-manuscript> for any that apply to your paper. In your rebuttal letter you should indicate your response to the reviewers\' and editors\' comments, the changes you have made in the manuscript, and include either an excerpt of the revised text or the location (eg: page and line number) where each change can be found. Please submit a clean version of the paper as the main article file; a version with changes marked should be uploaded as a marked up manuscript.

In addition, we request that you upload any figures associated with your paper as individual TIF or EPS files with 300dpi resolution at resubmission; please read our figure guidelines for more information on our requirements: <http://journals.plos.org/plosmedicine/s/figures>. While revising your submission, please upload your figure files to the PACE digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <PLOSMedicine@plos.org>.

We expect to receive your revised manuscript by Dec 05 2019 11:59PM. Please email us (<plosmedicine@plos.org>) if you have any questions or concerns.

\*\*\*Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.\*\*\*

We ask every co-author listed on the manuscript to fill in a contributing author statement, making sure to declare all competing interests. If any of the co-authors have not filled in the statement, we will remind them to do so when the paper is revised. If all statements are not completed in a timely fashion this could hold up the re-review process. If new competing interests are declared later in the revision process, this may also hold up the submission. Should there be a problem getting one of your co-authors to fill in a statement we will be in contact. YOU MUST NOT ADD OR REMOVE AUTHORS UNLESS YOU HAVE ALERTED THE EDITOR HANDLING THE MANUSCRIPT TO THE CHANGE AND THEY SPECIFICALLY HAVE AGREED TO IT. You can see our competing interests policy here: <http://journals.plos.org/plosmedicine/s/competing-interests>.

Please use the following link to submit the revised manuscript:

<https://www.editorialmanager.com/pmedicine/>

Your article can be found in the \"Submissions Needing Revision\" folder.

To enhance the reproducibility of your results, we recommend that you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see <http://journals.plos.org/plosmedicine/s/submission-guidelines#loc-methods>.

Please ensure that the paper adheres to the PLOS Data Availability Policy (see <http://journals.plos.org/plosmedicine/s/data-availability>), which requires that all data underlying the study\'s findings be provided in a repository or as Supporting Information. For data residing with a third party, authors are required to provide instructions with contact information for obtaining the data. PLOS journals do not allow statements supported by \"data not shown\" or \"unpublished results.\" For such statements, authors must provide supporting data or cite public sources that include it.

We look forward to receiving your revised manuscript.

Sincerely,

Adya Misra, PhD

Senior Editor

PLOS Medicine

[plosmedicine.org](http://plosmedicine.org)

\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--

Requests from the editors:

Title: please include a study descriptor to adhere to PLOS Medicine style. our title must be nondeclarative and not a question. It should begin with main concept if possible. \"Effect of\" should be used only if causality can be inferred, i.e., for an RCT. Please place the study design (\"A randomized controlled trial,\" \"A retrospective study,\" \"A modelling study,\" etc.) in the subtitle (ie, after a colon).

Abstract- please clarify if a causal association can be inferred from population studies? Please consider toning down or removing

Abstract-please provide population demographics, ie where the cohorts are from including names of hospitals or countries as appropriate

Abstract Please introduce FLC ratio on first view

Abstract background- please rephrase the first sentence to "In studies including the general population.." or similar for clarity

Abstract methods and findings-please include a limitation of your work as the last sentence of this section

Abstract methods section requires clarification. Please simplify the text in the abstract to explain the FLC ratio/LC MG measurement. In line 31-33 you say "Further, to assess the

32 association between a light-chain (LC) MG (defined as an FLC ratio outside the renal

33 reference range with an increased level of the involved light chain) two other cohorts were

34 also studied...". Could you clarify what association is being referred to here?

At this stage, we ask that you include a short, non-technical Author Summary of your research to make findings accessible to a wide audience that includes both scientists and non-scientists. The Author Summary should immediately follow the Abstract in your revised manuscript. This text is subject to editorial change and should be distinct from the scientific abstract. Please

see our author guidelines for more information: <https://journals.plos.org/plosmedicine/s/revising-your-manuscript#loc-author-summary>

Did your study have a prospective protocol or analysis plan? Please state this (either way) early in the Methods section. a) If a prospective analysis plan (from your funding proposal, IRB or other ethics committee submission, study protocol, or other planning document written before analyzing the data) was used in designing the study, please include the relevant prospectively written document with your revised manuscript as a Supporting Information file to be published alongside your study, and cite it in the Methods section. A legend for this file should be included at the end of your manuscript. b) If no such document exists, please make sure that the Methods section transparently describes when analyses were planned, and when/why any data-driven changes to analyses took place. c) In either case, changes in the analysis---including those made in response to peer review comments---should be identified as such in the Methods section of the paper, with rationale.

For all observational studies, in the manuscript text, please indicate: (1) the specific hypotheses you intended to test, (2) the analytical methods by which you planned to test them, (3) the analyses you actually performed, and (4) when reported analyses differ from those that were planned, transparent explanations for differences that affect the reliability of the study\'s results. If a reported analysis was performed based on an interesting but unanticipated pattern in the data, please be clear that the analysis was data-driven.

Line 100- Please introduce MGRS at first view

Please provide p values along with 95% CI where appropriate

Lines 164-165 require clarification- please can you explain what is meant by "more had a history of ..." etc?

Please ensure that the study is reported according to the STROBE guideline, and include the completed STROBE checklist as Supporting Information. Please add the following statement, or similar, to the Methods: \"This study is reported as per the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guideline (S1 Checklist).\"

The STROBE guideline can be found here: <http://www.equator-network.org/reporting-guidelines/strobe/>

When completing the checklist, please use section and paragraph numbers, rather than page numbers.

Please present and organize the Discussion as follows: a short, clear summary of the article\'s findings; what the study adds to existing research and where and why the results may differ from previous research; strengths and limitations of the study; implications and next steps for research, clinical practice, and/or public policy; one-paragraph conclusion.

Comments from the reviewers:

Reviewer \#1: This is a retrospective analysis of data collected prospectively for other causes from 3 different sources, used to analyze if there is a correlation between CKD progression and MG (prognostic significance of MGUS in CKD patients). Hypotheses are well defined by the authors.

First, as they are using data collected for other purposes, adding many variables to the statistical analysis limits the researchers\' ability to determine cause and effect. It is difficult to assess correlation using a retrospective study (RS) design, as RS are subject to numerous threats to validity (limiting interpretation and generalizability of results): the results should be considered as preliminary. Thus, the authors should be very cautious in their conclusions.

Also, data collection comes from 3 differents sources, with different inclusion criteria, data collected, etc\... Define if MG was detected by serum protein electrophoresis, if then patients underwent serum immunosubtraction and/or immunofixation (Immunofixation of a 24 h urine specimen performed to test for Bence Jones protein?). The diagnostic criteria for MGUS also should be included in this article and not referred for readers to the 3 studies used for it (these should all be included in the article itself): it would be great if authors could clarify eGFR formula used (CKD-EPI, MDRD 4\...) and include the definition of MG/MGUS. Specify type of Ig related MG if possible.

There is a low proportion of events (1.6% including all 3 studies, 55 patients from 3478), which limits statistical power to detect associations: authors should write about their study SUGGESTING X or Y are/aren\'t risk factors, but that further prospective studies are neccessary to clarify.

It would be interesting to know some serologies in these patients, as MG has been related to them (herpes virus, EBV, etc): Babel N, Schwarzmann F, Pruss A, et al. Monoclonal gammopathy of undetermined significance (MGUS) is associated with an increased frequency of Epstein‐Barr Virus (EBV) - Latently infected B lymphocytes in long‐term renal transplant patients. Transplant Proc 2004; 36: 2679; Regamey N, Hess V, Passweg J, et al. Infection with human herpesvirus 8 and transplant‐associated gammopathy. Transplantation 2004; 77: 1551.

Include Monoclonal gammopathy after liver transplantation: a risk factor for long‐term medical complications other than malignancies (DOI 10.1111/j.1432-2277.2011.01362.x), as they refer to CKD and MG (although in liver Tx recipients).

Overall, the results indeed suggested that there might be no association between CKD and MG, but no clear cut conclusion should be drawn from this (I would change their strong conclusion phrasing).

I believe it is an interesting topic for nephrologists, as nowadays the number of patients with MG that reach our clinics is growing.

Reviewer \#2: I confine my remarks to statistical aspects of this paper. The general approach is fine, but I do have some issues to resolve before I can recommend publication.

One general thing is that I would move the supplemental figures into the text.

Line 55-56: This is too strong. This accepts the null. If you want to make this statement, you would have to do tests of equivalence.

Line 130-131: In general, this is not a reason to not do power analysis. If the authors had done power analysis and found that they needed a larger N, then they would have had to either find more data or do a different analysis. In this specific case, since N is so large, it\'s not a problem.

Line 137-140 How many extreme points were there? Also, why not use robust Cox regression?

Line 141-143 Why was this done? Here, statistical significance is not the issue. Also, the authors don\'t seem to use the results of these analyses (unless I missed something)

Line 148-149 Good!

Line 150 \"Stratified\" usually means \"separate\" I\'m not sure that this is what is meant here. Was each cohort analyzed separately? It doesn\'t look like that was done, from the results. Please clarify. (An alternative would be a multilevel model, if the authors are worried about dependent errors).

Line 154: Good

Tables: Why are some sections blank?

Peter Flom

Reviewer \#3: Fenton et al. reported the association between MGUS and CKD and found that no association with the progression of CKD. The statistical analyses wee well performed. However, it is difficult to find the role of MGUS for the progression of CKD. The presented data is very limited and it is very difficult to understand the the meaning of the statistical analyses.

Among MGUS, amyloidosis is a rare but an important disease for the progression of CKD. In general, patients with amyloidosis has large amount of urinary protein excretion witch has some association with the progression of CKD. However, there is no description about amyloidosis. If the authors investigate the association between amyloidosis and the progression of CKD, the results would be useful for nephrologist. Just the definition of MGUS is too wide to consider the role for the progression of CKD.

There is no information on CRP. Since the infection has a key role for the progression of MGUS, the lack of such information should be avoided.

The data are collected at baseline visits. Although the authors described higher HR of ACR, urinary protein excretion may increase with time. So, it may be inadequate to investigate the role of urinary protein excretion by the baseline value.

Reviewer \#4: I have several comments:

\* In addition to renal transplantation or dialysis, do the authors have data to consider other endpoints, such as acute kidney injury, or rapid CKD progression?

\* The confidence intervals in the abstract are quite wide, so it is not inconceivable that the study did not have enough power to detect significance at the conventional 5% levels. Could the authors also discuss the possibly of over-adjusting in the multivariable model, for example, adjusting for common confounders between the exposures & the outcomes?

\* Could the authors provide more detail on the process of dealing with the extreme values. Was the truncation process applied to the creatinine measurements as well? Also, am I right that the measurements were not excluded, but rather it is their truncated values were used? How many measurements were truncated in the end?

Minor comments

\* How was eGFR calculated from creatinine?

\* Table 1: Inclusion criteria for RIISC: what does \"with eGFR decline\" mean?

Any attachments provided with reviews can be seen via the following link:

\[LINK\]

10.1371/journal.pmed.1003050.r002
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21 Jan 2020

Dear Dr. Fenton,

Thank you very much for re-submitting your manuscript \"Association between non-malignant monoclonal gammopathy and adverse outcomes in chronic kidney disease: a cohort study\" (PMEDICINE-D-19-03271R1) for review by PLOS Medicine.

I have discussed the paper with my colleagues and the academic editor and it was also seen again by xxx reviewers. I am pleased to say that provided the remaining editorial and production issues are dealt with we are planning to accept the paper for publication in the journal.

The remaining issues that need to be addressed are listed at the end of this email. Any accompanying reviewer attachments can be seen via the link below. Please take these into account before resubmitting your manuscript:

\[LINK\]

Our publications team (<plosmedicine@plos.org>) will be in touch shortly about the production requirements for your paper, and the link and deadline for resubmission. DO NOT RESUBMIT BEFORE YOU\'VE RECEIVED THE PRODUCTION REQUIREMENTS.

\*\*\*Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.\*\*\*

In revising the manuscript for further consideration here, please ensure you address the specific points made by each reviewer and the editors. In your rebuttal letter you should indicate your response to the reviewers\' and editors\' comments and the changes you have made in the manuscript. Please submit a clean version of the paper as the main article file. A version with changes marked must also be uploaded as a marked up manuscript file.

Please also check the guidelines for revised papers at <http://journals.plos.org/plosmedicine/s/revising-your-manuscript> for any that apply to your paper. If you haven\'t already, we ask that you provide a short, non-technical Author Summary of your research to make findings accessible to a wide audience that includes both scientists and non-scientists. The Author Summary should immediately follow the Abstract in your revised manuscript. This text is subject to editorial change and should be distinct from the scientific abstract.

We expect to receive your revised manuscript within 1 week. Please email us (<plosmedicine@plos.org>) if you have any questions or concerns.

We ask every co-author listed on the manuscript to fill in a contributing author statement. If any of the co-authors have not filled in the statement, we will remind them to do so when the paper is revised. If all statements are not completed in a timely fashion this could hold up the re-review process. Should there be a problem getting one of your co-authors to fill in a statement we will be in contact. YOU MUST NOT ADD OR REMOVE AUTHORS UNLESS YOU HAVE ALERTED THE EDITOR HANDLING THE MANUSCRIPT TO THE CHANGE AND THEY SPECIFICALLY HAVE AGREED TO IT.

Please ensure that the paper adheres to the PLOS Data Availability Policy (see <http://journals.plos.org/plosmedicine/s/data-availability>), which requires that all data underlying the study\'s findings be provided in a repository or as Supporting Information. For data residing with a third party, authors are required to provide instructions with contact information for obtaining the data. PLOS journals do not allow statements supported by \"data not shown\" or \"unpublished results.\" For such statements, authors must provide supporting data or cite public sources that include it.

If you have any questions in the meantime, please contact me or the journal staff on <plosmedicine@plos.org>.

We look forward to receiving the revised manuscript by Jan 28 2020 11:59PM.

Sincerely,

Adya Misra, PhD

Senior Editor

PLOS Medicine

[plosmedicine.org](http://plosmedicine.org)

\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--

Requests from Editors:

Author summary does not mention that the aim of the study was to compare the rates of MG in the general population with patients who have CKD. Since this is mentioned in the conclusions and discussion through the submission, please clarify if this information should be in the author summary

Please use p\<0.001 throughout, ensuring p values are provided along with 95% CI

Some summary demographic information would be useful in the abstract

Please remove spaces between refs where multiple ones cited

Data availability- please clarify if the data underlying various graphs and tables can be provided as supplementary information as per PLOS Data policy.

Introduction- Line 83 you say "MG is a prevalent condition". It would be helpful to provide context as to its prevalence or a reference for our non specialist readers

Comments from Reviewers:

Reviewer \#1: I think the text has much improved including the new information and toning down conclusions.

Reviewer \#2: The authors have addressed my concerns and I now recommend publication.

Peter Flom

Reviewer \#3: The revised version of the manuscript \'Association between non-malignant monoclonal gammopathy and adverse outcomes in chronic kidney disease: a cohort study\' by Dr Anthony Fenton and colleagues has improved very much. I still have some comments which the authors didi not respond.

The authors respondedto my comment that \"Unfortunately, CRP data were not available. To our knowledge, there is no substantial body of evidence that demonstrates that infection or an elevated CRP is a significant predictor of MGUS progression.\" But, high CRP is a risk factor of the progression of CKD (Am J Kidney Dis. 2016 ;68(6):873-881, Ren Fail. 2015 ;37(1):45-9.). Since the authors investigated the progression of CKD by non-malignant monoclonal gammopathy, the role of CRP has to be evaluated.

Reviewer \#4: The authors have addressed all my comments, thank you. Study limitations have been acknowledged appropriately, together with the need for future research and suggestions and suggestions on which direction this research could take place in.

Any attachments provided with reviews can be seen via the following link:

\[LINK\]

10.1371/journal.pmed.1003050.r004

Author response to Decision Letter 1

30 Jan 2020

###### 

Submitted filename: Response_to_reviewers.docx

###### 

Click here for additional data file.

10.1371/journal.pmed.1003050.r005
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3 Feb 2020

Dear Dr Fenton,

On behalf of my colleagues and the academic editor, Dr. Guiseppe Remuzzi, I am delighted to inform you that your manuscript entitled \"Association between non-malignant monoclonal gammopathy and adverse outcomes in chronic kidney disease: a cohort study\" (PMEDICINE-D-19-03271R2) has been accepted for publication in PLOS Medicine.

PRODUCTION PROCESS

Before publication you will see the copyedited word document (in around 1-2 weeks from now) and a PDF galley proof shortly after that. The copyeditor will be in touch shortly before sending you the copyedited Word document. We will make some revisions at the copyediting stage to conform to our general style, and for clarification. When you receive this version you should check and revise it very carefully, including figures, tables, references, and supporting information, because corrections at the next stage (proofs) will be strictly limited to (1) errors in author names or affiliations, (2) errors of scientific fact that would cause misunderstandings to readers, and (3) printer\'s (introduced) errors.

If you are likely to be away when either this document or the proof is sent, please ensure we have contact information of a second person, as we will need you to respond quickly at each point.

PRESS

A selection of our articles each week are press released by the journal. You will be contacted nearer the time if we are press releasing your article in order to approve the content and check the contact information for journalists is correct. If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact.

PROFILE INFORMATION

Now that your manuscript has been accepted, please log into EM and update your profile. Go to <https://www.editorialmanager.com/pmedicine>, log in, and click on the \"Update My Information\" link at the top of the page. Please update your user information to ensure an efficient production and billing process.

Thank you again for submitting the manuscript to PLOS Medicine. We look forward to publishing it.

Best wishes,

Adya Misra, PhD

Senior Editor

PLOS Medicine

[plosmedicine.org](http://plosmedicine.org)

[^1]: I have read the journal\'s policy and the authors of this manuscript have the following competing interests: PC has consulted for and advised the Binding Site, who produce the Freelite assay that has been used to measure the LC MGUS reported in this paper, and who carried out the intact immunoglobulin assays. SH is on the Board of Directors for The Binding Site who produce the Freelite assay used in this paper. MWT is a member of the Editorial Board of *PLOS Medicine*.
